在[F]胆碱检测到[Lu]Lu-PSMA-617后mCRPC疾病进展：一例前列腺癌异质性病例
mCRPC progression of disease after [Lu]Lu-PSMA-617 detected on [F]Choline: a case of PCa heterogeneity.
作者信息
Laudicella Riccardo, Minutoli Fabio, Russo Simona, Siracusa Massimiliano, Bambaci Michelangelo, Pagano Benedetta, Baldari Sergio
机构信息
Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, University of Messina, 98121, Italy.
Nuclear Medicine Unit, Humanitas Istituto Clinico Catanese, Misterbianco, 95045, Italy.
出版信息
Urol Case Rep. 2024 May 8;54:102750. doi: 10.1016/j.eucr.2024.102750. eCollection 2024 May.
Radioligand therapy with [Lu]Lu-PSMA is a theranostic approach for heavily treated mCRPC patients with positive PSMA PET in the absence of relevant PSMA-negative metastases assessed through CT, MRI, bone scan or FDG PET. In this case, we described a mCRPC patient treated with RLT with discordant PSA values and PSMA images, in which Choline PET confirmed a biochemically suspected disease progression (PD), showing metastatic lesions not revealed by PSMA imaging.
使用[镥]镥-PSMA进行放射性配体治疗是一种针对经过大量治疗的mCRPC患者的诊疗方法，这些患者PSMA PET呈阳性，且通过CT、MRI、骨扫描或FDG PET评估不存在相关的PSMA阴性转移灶。在此病例中，我们描述了一名接受放射性配体治疗的mCRPC患者，其PSA值与PSMA图像不一致，其中胆碱PET证实了生化检查怀疑的疾病进展（PD），显示出PSMA成像未发现的转移病灶。
Zotero 插件